Japan's Meiji Holdings says drug unit started late-stage trial for Covid-19 vaccine
TOKYO — Japan's Meiji Holdings said on Tuesday (Dec 13) its drug subsidiary had started a Phase Three trial of a messenger ribonucleic acid (mRNA)-based vaccine for Covid-19.
A medical worker fills a syringe with a dose of the Pfizer-BioNTech Covid-19 vaccine, at Tokyo Medical Center in Tokyo, Japan on Feb 17, 2021.
TOKYO — Japan's Meiji Holdings said on Tuesday (Dec 13) its drug subsidiary had started a Phase Three trial of a messenger ribonucleic acid (mRNA)-based vaccine for Covid-19.
Meiji Seika Pharma had started the late-stage trial among 780 subjects in Japan, with the test period running from November to April 2024, Meiji said in a statement.
The trial will test the effectiveness of the vaccine, developed by US-based Arcturus Therapeutics, in comparison with the mRNA shot developed by Pfizer Inc and BioNTech SE.
The trial was partially funded by Japan's health ministry, Meiji said, adding that it aimed at establishing a domestic production system for vaccines with a government subsidy.
Japan has depended largely on imported mRNA vaccines for its Covid-19 inoculation campaign.
Daiichi Sankyo of Japan said last month its mRNA vaccine candidate had been successful in a trial as a booster shot. The company plans to submit it to regulators in January 2023. REUTERS
Related topics
COVID-19 Covid-19 vaccine mRNA Edison ChenStay in the know. Anytime. Anywhere.
Subscribe to get daily news updates, insights and must reads delivered straight to your inbox.
By clicking subscribe, I agree for my personal data to be used to send me TODAY newsletters, promotional offers and for research and analysis.
